High-Dose Tigecycline in Elderly Patients with Pneumonia Due to Multidrug-Resistant Acinetobacter baumannii in Intensive Care Unit

Figures & data

Table 1 Demographic Characteristics of the 48 Elderly Patients with the Standard-Dose (SD) and High-Dose (HD) Tigecycline

Variables	SD TGC Group (n = 33)	HD TGC Group (n = 15)	P-value
Age (years), mean ± SD	77.64±9.26	70.33±9.01	0.993^a
Gender (male:female)	22/11	13/2	0.182^b
Weight (kg) mean ± SD	64.83±15.31	73.60±13.49	0.067^a
Source of Pneumonia
Hospital-acquired	5 (15.0%)	3 (20.0%)	0.685^b
Ventilator-associated	28 (85.0%)	12 (80.0%)
Co-morbidities
COPD	9 (27.3%)	1 (6.7%)	0.103^b
Invasive Procedures
Tracheotomy	2 (6.0%)	4 (26.7%)	0.067^b
Parenteral nutrition	10 (30.3%)	5 (33.3%)	0.543^b
Hospital stay before treatment	15.15± 9.08	14.47± 11.46	0.550 ^a
Previous carbapenem use	26 (78.8%)	10 (66.7%)	0.476^b
Days of tigecycline use	7.36±2.41	8.6±1.10	0.476^b
Charlson index	3.39±2.04	3.07±2.15	0.616 ^a
APACHE II score	18.69±5.75	17.47±3.95	0.457^a
Septic shock	7 (21.2%)	0	0.086^b

Notes: Data are expressed as absolute frequencies (n) and percentages (%). *Statistically significant (P≦0.05). ^aAnalysis of variance. ^bChi-square test.

Abbreviations: APACHE, Acute Physiology and Chronic Health Evaluation; SD, standard deviation.

Table 2 The Primary and Secondary Outcomes in Both Groups

Variable	SD TGC Group (n = 33)	HD TGC Group (n = 15)	P-value
Death at 30 days	13 (39.4%)	2 (13.3%)	0.098^b
Survival days	13.61±11.48	12.4±7.37	0.357^a
Number of hospital days	28.76±13.49	26.87±12.41	0.631^a
Microbiological eradication	8 (61.5%)	10 (66.7%)	0.02*^b

Notes: Data are expressed as absolute frequencies (n) and percentages (%). *Statistically significant (P≦0.05). ^aAnalysis of variance. ^bChi-square test.

Table 3 Combined Various Antimicrobials in Both Groups

Variable	Target Therapy		P-value
	SD TGC Group (n = 33)	HD TGC Group (n = 15)
Tigecycline combined with various antimicrobial	28 (84.8%)	14 (93.3%)	0.650^a
Carbapenems	12 (30.3%)	11 (73.3%)	0.017*^a
Aminoglycosides	1(3.03%)	1 (6.7%)	0.545^a
Beta-lactamase	16 (39.4%)	2 (13.3%)	0.054^a

Notes: Data are expressed as absolute frequencies (n) and percentages (%). *Statistically significant (P≦0.05). Carbapenems: Imipenem; meropenem; biapenem. Aminoglycosides: amikacin. Beta-lactamase: cefepime; ceftazidime; piperacillin and sulbactam. ^aChi-square test.

Table 4 Cox Regression Analysis of Factors Associated with 30-Day Mortality in 48 Elderly Patients

Variable	Multivariate Analysis
	HR	95% CI	P-value
COPD	11.63	(1.094–123.058)	0.042*
Tigecycline use of days	0.690	(0.515–0.926)	0.013*
Surgery before infection	79.276	(6.983–899.979)	0.000*

Note: *Statistically significant (P≦0.05).

Abbreviations: COPD, chronic obstructive pulmonary disease; HR, hazard ratio; CI, confidence interval.

Figure 1 Kaplan–Meier curves for mortality as a function of SD TGC or HD TGC by survival days.